# Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

> **NCT00352521** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 20 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** irinotecan
- **PROCEDURE:** dynamic contrast-enhanced magnetic resonance imaging

## Key facts

- **NCT ID:** NCT00352521
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2006-12
- **Final completion:** 2009-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352521, "Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00352521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*